Published in Nature on January 23, 2003
Protein networks in disease. Genome Res (2008) 5.65
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 4.79
The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell (2012) 4.29
Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci (2010) 3.81
Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A (2007) 3.37
Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med (2009) 2.66
Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J (2004) 2.24
Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener (2012) 2.11
A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A (2005) 1.88
Transcriptional signatures in Huntington's disease. Prog Neurobiol (2007) 1.86
A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A (2003) 1.84
Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol (2003) 1.77
Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci (2009) 1.73
Quantitative characterization of intrinsic disorder in polyglutamine: insights from analysis based on polymer theories. Biophys J (2007) 1.53
Regulation of proteasome activity in health and disease. Biochim Biophys Acta (2013) 1.52
Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A (2005) 1.52
Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Cell Biol (2008) 1.51
Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A (2005) 1.42
Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol (2010) 1.38
Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol (2010) 1.36
The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx (2005) 1.33
Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein. Genes Dev (2003) 1.33
A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. Biophys J (2010) 1.27
Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PLoS One (2007) 1.25
Activation of necroptosis in multiple sclerosis. Cell Rep (2015) 1.21
CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol Dis (2008) 1.19
Molecular origin of polyglutamine aggregation in neurodegenerative diseases. PLoS Comput Biol (2005) 1.17
Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim Biophys Acta (2011) 1.16
A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. Curr Opin Struct Biol (2010) 1.13
Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides. Biophys Chem (2011) 1.13
Formation and toxicity of soluble polyglutamine oligomers in living cells. PLoS One (2010) 1.12
PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J Cell Biol (2006) 1.12
Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum (2008) 1.11
Huntington's Disease. Cold Spring Harb Perspect Biol (2011) 1.11
Oxidative stress in neurodegeneration. Adv Pharmacol Sci (2011) 1.09
Allele-selective inhibition of trinucleotide repeat genes. Drug Discov Today (2012) 1.08
Bax-like protein Drob-1 protects neurons from expanded polyglutamine-induced toxicity in Drosophila. EMBO J (2005) 1.08
Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem (2012) 1.07
Direct and selective elimination of specific prions and amyloids by 4,5-dianilinophthalimide and analogs. Proc Natl Acad Sci U S A (2008) 1.06
Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx (2004) 1.05
Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias. Neurochem Res (2011) 1.04
An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem (2010) 1.03
MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1. Cell (2015) 1.02
Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms. EMBO Mol Med (2009) 1.00
Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. Genetics (2011) 1.00
Simple sequence repeats provide a substrate for phenotypic variation in the Neurospora crassa circadian clock. PLoS One (2007) 1.00
Suppression of the HSF1-mediated proteotoxic stress response by the metabolic stress sensor AMPK. EMBO J (2014) 0.97
Mechanism of cis-inhibition of polyQ fibrillation by polyP: PPII oligomers and the hydrophobic effect. Biophys J (2009) 0.95
Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation. Proc Natl Acad Sci U S A (2004) 0.94
Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease. Chem Biol (2011) 0.94
The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. BMC Biochem (2007) 0.93
Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J Biol Chem (2011) 0.93
Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Mol Neurodegener (2012) 0.93
Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. J Neurosci Res (2009) 0.92
The many faces of autophagy dysfunction in Huntington's disease: from mechanism to therapy. Drug Discov Today (2014) 0.92
SCAMP5 links endoplasmic reticulum stress to the accumulation of expanded polyglutamine protein aggregates via endocytosis inhibition. J Biol Chem (2009) 0.90
Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neurosci (2012) 0.90
Network-based identification of biomarkers coexpressed with multiple pathways. Cancer Inform (2014) 0.88
Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. Br J Pharmacol (2010) 0.88
Repeat-associated non-AUG translation and its impact in neurodegenerative disease. Neurotherapeutics (2014) 0.88
Aggregation formation in the polyglutamine diseases: protection at a cost? Mol Cells (2013) 0.87
Neurodegenerative disorders: Parkinson's disease and Huntington's disease. J Neurol Neurosurg Psychiatry (2005) 0.87
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice. BMC Neurosci (2004) 0.87
Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Mol Neurobiol (2012) 0.86
Reversible aggregation of PABPN1 pre-inclusion structures. Nucleus (2011) 0.86
Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues. Prion (2013) 0.86
A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease. PLoS One (2014) 0.85
Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease. Hum Mol Genet (2014) 0.84
Temporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutation. PLoS One (2012) 0.84
Amyloid-like fibril formation by polyQ proteins: a critical balance between the polyQ length and the constraints imposed by the host protein. PLoS One (2012) 0.84
Lost after translation: insights from pulmonary surfactant for understanding the role of alveolar epithelial dysfunction and cellular quality control in fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol (2015) 0.83
The Ubiquitin-Proteasome System in Huntington's Disease: Are Proteasomes Impaired, Initiators of Disease, or Coming to the Rescue? Biochem Res Int (2012) 0.83
Basal and stress-induced Hsp70 are modulated by ataxin-3. Cell Stress Chaperones (2012) 0.83
Modulation of mutant huntingtin N-terminal cleavage and its effect on aggregation and cell death. Neurotox Res (2010) 0.83
Therapeutic prospects for spinocerebellar ataxia type 2 and 3. Drugs Future (2009) 0.82
Wall teichoic acid protects Staphylococcus aureus from inhibition by Congo red and other dyes. J Antimicrob Chemother (2012) 0.82
Modifiers of mutant huntingtin aggregation: functional conservation of C. elegans-modifiers of polyglutamine aggregation. PLoS Curr (2011) 0.81
High-throughput screen of natural product extracts in a yeast model of polyglutamine proteotoxicity. Chem Biol Drug Des (2014) 0.80
Pathological accumulation of atrophin-1 in dentatorubralpallidoluysian atrophy. Int J Clin Exp Pathol (2011) 0.80
Therapeutic Strategies in Huntington's Disease. J Clin Neurol (2006) 0.80
Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset. PLoS One (2007) 0.79
Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia. Neurobiol Dis (2010) 0.79
Soluble oligomers are sufficient for transmission of a yeast prion but do not confer phenotype. J Cell Biol (2013) 0.79
The core-inversible micelles for hydrophilic drug delivery. Chem Commun (Camb) (2013) 0.79
Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression. Mol Neurodegener (2013) 0.79
A single-nucleotide polymorphism in the EAP1 gene is associated with amenorrhea/oligomenorrhea in nonhuman primates. Endocrinology (2011) 0.79
Large-scale RNA interference screening in mammalian cells identifies novel regulators of mutant huntingtin aggregation. PLoS One (2014) 0.79
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. J Cell Mol Med (2015) 0.78
Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease. BMC Neurosci (2006) 0.78
Polyglutamine aggregates impair lipid membrane integrity and enhance lipid membrane rigidity. Biochim Biophys Acta (2016) 0.78
Stable polyglutamine dimers can contain β-hairpins with interdigitated side chains-but not α-helices, β-nanotubes, β-pseudohelices, or steric zippers. Biophys J (2014) 0.77
Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds. Oxid Med Cell Longev (2015) 0.77
Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntington's disease R6/2 model. Sci Rep (2015) 0.76
Network Medicine: New Paradigm in the -Omics Era. Anat Physiol (2011) 0.76
Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.75
Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease. Exp Neurobiol (2014) 0.75
Inhibition of Aggregation of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington's Disease. Mol Ther (2015) 0.75
Comparison of mHTT Antibodies in Huntington's Disease Mouse Models Reveal Specific Binding Profiles and Steady-State Ubiquitin Levels with Disease Development. PLoS One (2016) 0.75
Protein aggregation activates erratic stress response in dietary restricted yeast cells. Sci Rep (2016) 0.75
Inositol 1,4,5-tripshosphate receptor, calcium signaling, and polyglutamine expansion disorders. Curr Top Membr (2010) 0.75
Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J (2008) 12.89
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol (2005) 11.63
Autophagy in cell death: an innocent convict? J Clin Invest (2005) 10.70
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science (2005) 7.98
Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell (2008) 7.61
Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J Biol Chem (2006) 3.77
Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol (2008) 3.59
A decade of caspases. Oncogene (2003) 3.55
Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol (2003) 3.52
Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol (2010) 3.51
Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A (2007) 3.37
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell (2007) 3.21
Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell (2011) 2.98
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell (2011) 2.58
Negative regulation of Vps34 by Cdk mediated phosphorylation. Mol Cell (2010) 2.57
Cell death assays for drug discovery. Nat Rev Drug Discov (2011) 2.51
A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell (2010) 2.40
Selective inhibition of eukaryotic translation initiation factor 2 alpha dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic beta-cell dysfunction and apoptosis. J Biol Chem (2006) 2.26
Antigen-mediated T cell expansion regulated by parallel pathways of death. Proc Natl Acad Sci U S A (2008) 2.20
Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 2.10
Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab (2008) 2.06
Caspase-11 regulates cell migration by promoting Aip1-Cofilin-mediated actin depolymerization. Nat Cell Biol (2007) 2.01
Autophagy limits Listeria monocytogenes intracellular growth in the early phase of primary infection. Autophagy (2007) 1.92
Automated neurite extraction using dynamic programming for high-throughput screening of neuron-based assays. Neuroimage (2007) 1.92
Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model. J Neurosci Res (2010) 1.89
Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol (2013) 1.89
The Jekyll and Hyde functions of caspases. Dev Cell (2009) 1.87
Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett (2005) 1.72
Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell (2012) 1.72
Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci (2012) 1.69
Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A (2008) 1.69
LKB1--a master tumour suppressor of the small intestine and beyond. Nat Rev Cancer (2002) 1.62
Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci U S A (2010) 1.61
Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci (2002) 1.58
Control of basal autophagy by calpain1 mediated cleavage of ATG5. Autophagy (2010) 1.51
Cochlin produced by follicular dendritic cells promotes antibacterial innate immunity. Immunity (2013) 1.50
Mitochondrial electron transport chain complex III is required for antimycin A to inhibit autophagy. Chem Biol (2011) 1.50
Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis. EMBO J (2004) 1.46
Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev (2007) 1.38
Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res (2006) 1.37
Control of life-or-death decisions by RIP1 kinase. Annu Rev Physiol (2013) 1.37
Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci U S A (2002) 1.36
A novel tracing algorithm for high throughput imaging Screening of neuron-based assays. J Neurosci Methods (2006) 1.35
Inhibition of cellular autophagy deranges dengue virion maturation. J Virol (2012) 1.32
A PHD finger motif in the C terminus of RAG2 modulates recombination activity. J Biol Chem (2005) 1.31
Dual role of sumoylation in the nuclear localization and transcriptional activation of NFAT1. J Biol Chem (2004) 1.31
Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem (2007) 1.27
Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5. Bioorg Med Chem Lett (2006) 1.26
Structural basis of RIP1 inhibition by necrostatins. Structure (2013) 1.23
c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1. Mol Cell (2007) 1.23
Activation of necroptosis in multiple sclerosis. Cell Rep (2015) 1.21
A genome-wide RNAi screen reveals multiple regulators of caspase activation. J Cell Biol (2007) 1.17
Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans. J Neurosci (2002) 1.15
Flightless-I regulates proinflammatory caspases by selectively modulating intracellular localization and caspase activity. J Cell Biol (2008) 1.14
Chaperone-mediated autophagy degrades mutant p53. Genes Dev (2013) 1.11
Regulator of calcineurin 1 (RCAN1) facilitates neuronal apoptosis through caspase-3 activation. J Biol Chem (2011) 1.11
Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep (2015) 1.09
Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagy. J Cell Biol (2009) 1.09
Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells. J Neurochem (2008) 1.08
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest (2013) 1.08
A critical role of eEF-2K in mediating autophagy in response to multiple cellular stresses. Autophagy (2009) 1.04
Pharmacologic agents targeting autophagy. J Clin Invest (2015) 1.04
Bax, caspase-2, and caspase-3 are required for ovarian follicle loss caused by 4-vinylcyclohexene diepoxide exposure of female mice in vivo. Endocrinology (2003) 1.04
Prion pathogenesis is independent of caspase-12. Prion (2007) 1.03
Mechanisms of cell death in polyglutamine expansion diseases. Curr Opin Pharmacol (2004) 1.02
A novel small molecule regulator of guanine nucleotide exchange activity of the ADP-ribosylation factor and golgi membrane trafficking. J Biol Chem (2008) 1.00
Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett (2007) 0.96
Alpha-synuclein oligomerization: a role for lipids? Trends Neurosci (2003) 0.94
A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. J Am Chem Soc (2002) 0.94
Role of protein misfolding in DFNA9 hearing loss. J Biol Chem (2010) 0.94
A computational framework for studying neuron morphology from in vitro high content neuron-based screening. J Neurosci Methods (2010) 0.90
Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels. J Neuropathol Exp Neurol (2006) 0.89
ICP34.5-dependent and -independent activities of salubrinal in herpes simplex virus-1 infected cells. Virology (2008) 0.88
Dissociation between neurodegeneration and caspase-11-mediated activation of caspase-1 and caspase-3 in a mouse model of amyotrophic lateral sclerosis. J Neurosci (2003) 0.88
LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. Anticancer Res (2007) 0.88
Arctigenin preferentially induces tumor cell death under glucose deprivation by inhibiting cellular energy metabolism. Biochem Pharmacol (2012) 0.87
Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorg Med Chem Lett (2008) 0.85
Live imaging and single-cell analysis reveal differential dynamics of autophagy and apoptosis. Autophagy (2013) 0.84
Caspase-11 is not necessary for chemotherapy-induced intestinal mucositis. DNA Cell Biol (2004) 0.83
Structure-activity relationship and liver microsome stability studies of pyrrole necroptosis inhibitors. Bioorg Med Chem Lett (2008) 0.82
Structure-activity relationship studies of salubrinal lead to its active biotinylated derivative. Bioorg Med Chem Lett (2005) 0.82
Modification of protein sub-nuclear localization by synthetic phosphoinositides: evidence for nuclear phosphoinositide signaling mechanisms. Adv Enzyme Regul (2005) 0.80
Identification of small molecule inhibitors of neurite loss induced by Aβ peptide using high content screening. J Biol Chem (2012) 0.80
Modification of BECN1 by ISG15 plays a crucial role in autophagy regulation by type I IFN/interferon. Autophagy (2015) 0.80
An Image Based System Biology Approach for Alzheimer's Disease Pathway Analysis. IEEE NIH Life Sci Syst Appl Workshop (2009) 0.79
Identification of a small molecule activator of novel PKCs for promoting glucose-dependent insulin secretion. Cell Res (2010) 0.79
Optimization of tricyclic Nec-3 necroptosis inhibitors for in vitro liver microsomal stability. Bioorg Med Chem Lett (2012) 0.79
A novel necroptosis inhibitor-necrostatin-21 and its SAR study. Bioorg Med Chem Lett (2013) 0.78
A degradative detour for mutant TP53. Autophagy (2013) 0.76
Releasing the nerve cell killers. Nat Med (2002) 0.75
Cell biology: Death by deacetylation. Nature (2012) 0.75
To kill or to arrest: that is the new question for Apaf-1. Mol Cell (2007) 0.75
Junying Yuan: changing avenues without losing focus. Interview by Nicole LeBrasseur. J Cell Biol (2007) 0.75
Parcs is a dual regulator of cell proliferation and apaf-1 function. J Biol Chem (2008) 0.75
A cellular response to an internal energy crisis. Cell (2005) 0.75
Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers. Bioorg Med Chem Lett (2010) 0.75
Life and death in paradise. Nat Cell Biol (2002) 0.75